Recent advances in systemic therapies for metastatic breast cancer have yielded significant survival improvements. Treatment selection is increasingly guided by tumor biology, incorporating biomarker-driven strategies as per contemporary NCCN guidelines. This paradigm shift emphasizes molecular profiling to personalize therapeutic regimens, enhancing clinical outcomes while necessitating ongoing evidence synthesis to optimize sequencing and combination approaches in the evolving metastatic landscape.